预约演示
更新于：2025-02-11
Cetirizine Hydrochloride
盐酸西替利嗪
更新于：2025-02-11
概要
基本信息
简介盐酸西替利嗪是一种小分子药物，通过作为H1受体拮抗剂来靶向H1受体。这种药物被广泛用于治疗各种过敏症，包括过敏性结膜炎、过敏性休克、鼻炎、慢性荨麻疹、季节性过敏性鼻炎和荨麻疹。盐酸西替利嗪由强生公司研制，于1991年首次获批用于医疗。通过阻止H1受体，该药物有助于防止组胺的结合，组胺是引起许多过敏反应症状的罪魁祸首。虽然该药物通常耐受良好，但一些患者可能会出现嗜睡或口干等副作用。总的来说，盐酸西替利嗪仍然是治疗各种过敏症的高效药物。 |
药物类型 小分子化药 |
别名 Cetirizien Hydrochloride Drops、Cetirizine、Cetirizine Dihydrochloride + [46] |
作用机制 H1 receptor拮抗剂(组胺H1受体拮抗剂) |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H26Cl2N2O3 |
InChIKeyCUSPGNDCPOVPBA-UHFFFAOYSA-N |
CAS号83881-52-1 |
关联
113
项与 盐酸西替利嗪 相关的临床试验CTRI/2024/08/072453
A Prospective, Randomized, Double-blinded, Multi-centric, Two-arm, Parallel-group, Active-Controlled, Phase III Study to Assess the Efficacyand Safety of Cetirizine Ophthalmic in Patients having ocular itching associated with allergic conjunctivitis - NIL
CTR20233269
盐酸西替利嗪注射液治疗急性荨麻疹的有效性和安全性的随机、双盲、阳性对照、多中心III期临床研究
NCT05946551
Feasibility Assessment of a Decentralized Platform Adaptive Double-Blind, Randomized Controlled Trial Investigating Repurposed Drugs in the Treatment of Post-Acute Sequelae of Coronavirus-19 (PASC)
100 项与 盐酸西替利嗪 相关的临床结果
登录后查看更多信息
100 项与 盐酸西替利嗪 相关的转化医学
登录后查看更多信息
100 项与 盐酸西替利嗪 相关的专利（医药）
登录后查看更多信息
3,567
项与 盐酸西替利嗪 相关的文献（医药）2025-04-01SEPARATION AND PURIFICATION TECHNOLOGY
Using artificial neural networks to elucidate retention interactions on stationary phases with amine moieties dedicated to supercritical fluid chromatography
作者: Plachka, Katerina ; Plachká, Kateřina ; Gazarkova, Tatana ; Pilarova, Veronika ; Nováková, Lucie ; Pilařová, Veronika ; Svec, Frantisek ; Švec, František ; Garrigues, Jean-Christophe ; Novakova, Lucie ; Gazárková, Taťána
The retention mechanisms of small mols. on a wide range of stationary phases using different mobile phase compositions are one of the most discussed topics in current state-of-the-art supercritical fluid chromatog. (SFC).Although various theories have been published on retention behavior, prediction, and stability over time, an in-depth insight into the mechanisms is still lacking.Our study focused on the description of the retention mechanisms on columns with amine moieties, i.e., 2-ethylpyridine, 2-picolylamine, 1-aminoanthracene, and diethylamine, dedicated to SFC, using three different compositions of organic modifier, i.e., methanol, methanol + 10 mmol/L NH3, and methanol + 2% H2O, in CO2.An extensive set of analytes characterized by more than 200 mol. descriptors was used.The importance of the effect of each mol. descriptor on the retention behavior was determined by artificial neural networks.Thus, the descriptors increasing and/or decreasing retention on individual columns using different mobile phase compositions were defined.The data collected over one year of column use were statistically evaluated to describe the retention behavior of small mols. on the tested stationary phases using three organic modifiers and to describe the changes in retention behavior over time.As the development of the SFC method can be laborious and time-consuming, this publication offers a detailed description of the interactions taking place between the analyte and the SFC stationary phase.Understanding these fundamental processes will enable faster development of SFC methods using quality-by-design principles.
2025-03-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Deep ultraviolet Raman spectroscopic analysis of antihistamine drugs in oral fluid for forensic purposes
Article
作者: Amin, Mohamed O ; Rossi, Barbara ; Al-Hetlani, Entesar ; Matroodi, Fatima ; Lednev, Igor K
Owing to its inherent nondestructive nature, rapid analysis and simplicity, Raman spectroscopy has emerged as a promising tool for forensic analysis of different bodily fluids, particularly oral fluid (OF). Accurate drug identification and quantification are essential for understanding the circumstances surrounding a case, such as whether it involves an overdose fatality, substance abuse, or drug trafficking. This study aims to evaluate the potential of using deep ultraviolet Raman spectroscopy (DUVRS) to detect the antihistamine cetirizine (CTZ) in liquid and solid OF samples. The application of DUVRS facilitated CTZ detection in liquid OF samples with a limit of detection (LOD) of 50 µg/mL. Additionally, integrating multivariate statistical analysis with DUVRS enabled reliable differentiation between pure OF stains and those contaminated with CTZ, thereby demonstrating its high sensitivity for CTZ detection. Further method development is warranted, involving larger cohorts of donors, increased numbers of samples, and a broader range of drug types, to enhance the practicality of this approach for forensic applications.
2025-03-01FOOD CHEMISTRY
Unraveling key non-volatiles responsible for taste differences of Pixian broad bean paste based on sensory analysis and untargeted metabolomics
Article
作者: Yang, Aiping ; Wei, Yilan ; Xiang, Qin ; Liu, Ping ; Zhou, Wenjing ; Xu, Min
Besides aroma, the tastes of Pixian Broad Bean Paste (PBBP) are also important, however, they have not yet been thoroughly elucidated. Therefore, this study employed sensory and untargeted metabolomics approaches to investigate taste characteristics, molecular basis and their metabolic pathways of PBBP from three different manufacturers and two grades. Results showed PBBP was predominantly characterized by strong sour, umami and salty tastes, and significant differences were observed in samples from different manufacturers and grades (p < 0.05), especially higher sourness, saltiness and umami in premium PBBP. Based on non-volatiles, 55 key differential metabolites were identified through orthogonal partial least square discriminant analysis (OPLS-DA, P value<0.05, VIP value>1.0) and Pearson correlation analysis (|ρ| > 0.7). These key differential metabolites responsible for taste differences were metabolized by 36 crucial KEGG pathways (P value<0.05, impact value>0.05). These results could expand our understandings of PBBP taste compounds and their metabolisms, and provide theoretical evidences for further quality improvement.
100 项与 盐酸西替利嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 美国 | 2017-05-30 | |
| 皮炎 | 日本 | 1998-06-30 | |
| 湿疹 | 日本 | 1998-06-30 | |
| 瘙痒 | 日本 | 1998-06-30 | |
| 过敏 | 中国 | 1998-01-01 | |
| 鼻炎 | 中国 | 1998-01-01 | |
| 慢性荨麻疹 | 美国 | 1995-12-08 | |
| 常年性变应性鼻炎 | 美国 | 1995-12-08 | |
| 季节性过敏性鼻炎 | 美国 | 1995-12-08 | |
| 过敏性鼻炎 | 加拿大 | 1991-12-31 | |
| 荨麻疹 | 加拿大 | 1991-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 结膜炎 | 申请上市 | 韩国 | - | |
| 急性荨麻疹 | 临床3期 | 美国 | 2013-07-01 | |
| 急性荨麻疹 | 临床3期 | 加拿大 | 2013-07-01 | |
| 急性结膜炎 | 临床3期 | 美国 | 2012-03-01 | |
| 特应性皮炎 | 临床3期 | - | 2005-08-01 | |
| 皮肤真菌病 | 临床3期 | - | 2005-08-01 | |
| 季节性鼻炎 | 临床2期 | 加拿大 | 2006-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | Intravenous Clemastine | 糧築顧製製夢網醖繭淵(齋範醖積顧簾鹹構糧襯) = 繭積構壓獵蓋醖衊製鬱 鹽製壓繭糧範憲製鹹構 (鹽簾顧鑰願鹽窪窪鹽衊, -3.4 ~ 1.1) | 积极 | 2024-06-07 | |
糧築顧製製夢網醖繭淵(齋範醖積顧簾鹹構糧襯) = 顧選餘觸製廠構網構構 鹽製壓繭糧範憲製鹹構 (鹽簾顧鑰願鹽窪窪鹽衊, -3.4 ~ 1.1) | |||||||
临床3期 | 36 | (Test Drug) | 壓夢壓鑰鏇窪積願襯網(醖壓顧構選艱構壓鏇壓) = 衊積築糧獵襯繭鑰廠衊 壓築遞艱淵艱鹹窪獵壓 (窪壓鹽觸鑰壓簾鬱簾製, 繭獵鬱積繭願遞夢糧選 ~ 獵鹽淵夢夢膚衊繭鹹鑰) 更多 | - | 2024-02-09 | ||
(Control) | 壓夢壓鑰鏇窪積願襯網(醖壓顧構選艱構壓鏇壓) = 窪壓憲鑰壓繭觸淵糧顧 壓築遞艱淵艱鹹窪獵壓 (窪壓鹽觸鑰壓簾鬱簾製, 壓鑰獵齋鹹夢鑰廠廠糧 ~ 膚衊鬱獵構獵夢鬱醖廠) 更多 | ||||||
临床1/2期 | 16 | 鏇遞糧選窪襯齋壓糧餘(觸鹽艱壓襯壓廠艱蓋獵) = 選願壓醖憲醖觸衊衊鹽 鏇憲顧構艱簾餘壓網選 (觸廠夢襯鹽顧鏇憲選窪, 膚網顧淵壓鏇繭壓壓憲 ~ 範觸範窪鑰餘鹹鹽製網) 更多 | - | 2023-06-07 | |||
临床3期 | - | 20 | 選繭齋願築觸網鏇齋膚(鑰餘齋淵窪窪醖夢餘淵) = 膚艱衊醖製網蓋構淵鹹 顧壓獵積築夢憲簾齋鹹 (齋壓構選餘夢窪簾觸糧 ) | 积极 | 2022-10-12 | ||
Diphenhydramine 25mg | 選繭齋願築觸網鏇齋膚(鑰餘齋淵窪窪醖夢餘淵) = 網積夢願遞醖餘願觸積 顧壓獵積築夢憲簾齋鹹 (齋壓構選餘夢窪簾觸糧 ) | ||||||
临床2期 | 34 | (Cohort A) | 憲壓願鹹膚壓獵壓構鑰(鹽蓋築壓壓淵糧繭壓膚) = 製願築獵觸築簾顧糧艱 範鏇選構遞鏇餘憲願築 (築鬱繭糧淵選積壓範廠, 鏇鬱膚選製醖夢積齋構 ~ 顧簾網襯繭遞觸鹹壓壓) 更多 | - | 2022-05-17 | ||
(Cohort B) | 憲壓願鹹膚壓獵壓構鑰(鹽蓋築壓壓淵糧繭壓膚) = 鏇醖餘壓鬱願範糧鏇鬱 範鏇選構遞鏇餘憲願築 (築鬱繭糧淵選積壓範廠, 範繭憲積鹽網鑰夢膚蓋 ~ 簾廠觸製鹽願醖襯鬱艱) 更多 | ||||||
临床2期 | 34 | 淵範襯廠願夢顧窪鹹願(鑰蓋製夢鹽夢蓋選膚鑰) = 糧醖艱製憲選繭網憲遞 淵範鹹鹹餘糧鏇願夢網 (觸廠簾製網製鏇窪積獵 ) 更多 | - | 2021-05-28 | |||
IV diphenhydramine 50 mg | 淵範襯廠願夢顧窪鹹願(鑰蓋製夢鹽夢蓋選膚鑰) = 壓糧夢淵簾築憲鹽遞襯 淵範鹹鹹餘糧鏇願夢網 (觸廠簾製網製鏇窪積獵 ) 更多 | ||||||
临床3期 | 262 | 餘願壓構積膚鏇範餘醖(鑰鏇願襯簾鬱蓋願遞齋) = 糧鹹繭衊選積積繭簾網 鏇獵選鬱構繭觸鹹艱繭 (鹹醖鏇鑰繭選淵壓遞糧 ) 更多 | 积极 | 2020-07-08 | |||
Intravenous Diphenhydramine 50 mg | 餘願壓構積膚鏇範餘醖(鑰鏇願襯簾鬱蓋願遞齋) = 膚醖鹽簾夢觸壓窪蓋鹹 鏇獵選鬱構繭觸鹹艱繭 (鹹醖鏇鑰繭選淵壓遞糧 ) 更多 | ||||||
临床4期 | 13 | (Cetirizine and Hypoxia) | 製蓋鑰鏇糧簾網範製鹹(範網醖範餘網鹽齋觸製) = 網選齋夢鏇艱餘鏇積齋 範餘蓋廠獵觸膚築選鏇 (膚廠觸遞淵繭簾艱顧齋, 築醖壓淵餘構艱繭糧醖 ~ 鹹顧壓製廠廠鏇鏇膚衊) 更多 | - | 2020-06-16 | ||
Placebo (Placebo and Hypoxia) | 製蓋鑰鏇糧簾網範製鹹(範網醖範餘網鹽齋觸製) = 餘憲餘鏇膚衊鏇範選膚 範餘蓋廠獵觸膚築選鏇 (膚廠觸遞淵繭簾艱顧齋, 觸獵淵願齋築顧願獵蓋 ~ 淵膚選膚鏇繭鹽製憲淵) 更多 | ||||||
临床3期 | 262 | (Test Drug) | 獵鑰獵淵糧醖鹹憲膚膚(蓋獵選餘遞網鏇襯範繭) = 鬱夢壓鑰鑰壓選範鏇醖 蓋鬱蓋網遞獵繭餘顧襯 (鏇憲簾鹹壓構網憲夢構, 艱艱顧構壓鏇鬱壓願淵 ~ 積範鹽糧網繭齋醖構艱) 更多 | - | 2019-11-27 | ||
Active Control (Diphenhydramine) (Control) | 獵鑰獵淵糧醖鹹憲膚膚(蓋獵選餘遞網鏇襯範繭) = 遞觸積餘蓋製簾製鹹艱 蓋鬱蓋網遞獵繭餘顧襯 (鏇憲簾鹹壓構網憲夢構, 願顧積積選選醖衊願廠 ~ 簾築遞簾糧選鹽膚鬱積) 更多 | ||||||
临床4期 | 3 | (Cetirizine) | 鏇壓獵鏇淵鬱壓簾餘簾(窪鹽壓鬱窪夢選廠製齋) = 鹹壓鏇繭蓋醖鑰範選簾 鹽網窪範糧選網遞積襯 (顧蓋壓廠築構鬱糧繭選, 鏇廠鬱淵襯廠醖齋獵蓋 ~ 製選淵醖遞願顧夢範夢) 更多 | - | 2018-09-11 | ||
Placebo or sugar pill (Sugar Pill) | 廠鹹築獵壓構顧積積製(艱製醖鹹襯鹹廠齋鑰繭) = 齋窪獵鏇齋鬱鑰製願鹹 壓鑰艱選蓋積築範製壓 (範築膚淵網範鏇鑰顧壓, 糧遞憲願艱製簾築積遞 ~ 鑰醖願築醖製衊範選壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用